| Popis: |
Wenbin Liu,1,2,* Mingchao Zhang,3,* Jingli Tan,1,2 Hao Liu,1,2 Lijun Wang,1,2 Jingyang Liao,1,2 Dan Huang,1,2 Wang Jie,1,2 Xiaobao Jin1,2 1School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, People’s Republic of China; 2Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, Guangdong Pharmaceutical University, Guangzhou, People’s Republic of China; 3People’s Hospital of Foshan Nanhai Economy Development Zone, Foshan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xiaobao Jin; Wang Jie, Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, GuangDong Pharmaceutical University, Guangzhou, Guangdong, 510006, People’s Republic of China, Tel +861 358 056 5879, Fax +86020-3935 2184, Email jinxf2001@163.com; wangjie19870122@163.comBackground: Hyperuricemia (HUA), a common metabolic disorder associated with gout, renal dysfunction, and systemic inflammation, necessitates safer and more comprehensive therapeutic approaches. Traditional Tibetan medicine has a rich history of treating HUA. This study aimed to identify novel anti-hyperuricemic herb derived from traditional Tibetan medicine.Methods: Traditional Tibetan medicine prescriptions for HUA were analyzed using data mining techniques, identifying T. chebula as a high-frequency herb. Its phytochemical composition was characterized by UPLC-QE-Orbitrap-MS. Hyperuricemic rat models were treated with T. chebula to assess its effects on serum uric acid (UA) levels, renal inflammation, intestinal barrier integrity, and gut microbiota composition. Molecular and histological analyses evaluated its impact on key biomarkers.Results: Through data mining, we identified T. chebula as a promising candidate for HUA treatment. T. chebula demonstrated dose-dependent inhibition of xanthine oxidase (XOD) in vitro and significantly reduced serum UA levels and XOD activity in vivo. It restored gut barrier function by upregulating tight junction proteins (ZO-1, Occludin, Claudin-1) and reduced pro-inflammatory cytokines (IL-6, TNF-α). T. chebula improved renal function, reducing serum creatinine (Cre) and blood urea nitrogen (BUN) levels. Gut microbiota analysis revealed a favorable shift in microbial composition, with reductions in harmful bacteria (eg, Clostridium spp.) and increases in beneficial bacteria (eg, Roseburia). These effects aligned with the modulation of the gut-kidney axis.Conclusion: This study highlights the multi-target therapeutic potential of T. chebula in HUA management. By regulating the gut-kidney axis, T. chebula alleviates systemic inflammation, enhances intestinal and renal health, and addresses critical aspects of HUA pathology. These findings underscore the value of integrating traditional medicine with modern scientific methodologies to develop innovative treatments. Keywords: Terminalia chebula Retz., hyperuricemia, intestinal flora, renal, data mining |
